[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,49,77,101,123,155,206,240,277,304,328,359,381,407,429,453,490,515,535,562,602,623,651,700,721],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643879","phase-1-coq10-and-vitamin-e-for-off-target-radiation-toxicity-100643879",false,"NCT07668284","COQ10 and Vitamin E for Off-Target Radiation Toxicity","Evaluating the Safety and Efficacy of Coenzyme Q10 and Vitamin E Dual Therapy in Mitigating Chronic Off-Target Radiation Toxicity","Inclusion Criteria:\n\n1. Pathologically confirmed post-prostatectomy prostate, uterine (endometrial and cervical), or anal cancer.\n2. Scheduled for curative-intent, multi-fraction (at least 15 fractions) external-beam radiotherapy +\u002F- chemotherapy at the study site which does not involve re-irradiation to the same field.\n3. Age ≥ 19 years at the time of consent.\n4. Eastern Cooperative Oncology Group Performance Status ≤ 2.\n5. Life expectancy ≥ 6 months at the time of consent as determined by the participant's treating physician.\n6. Participants must be able to swallow soft-gel capsules.\n7. Participants must not have a disease significantly affecting drug absorption (e.g., resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction).\n8. Participants must agree to limit alcohol consumption to ≤ 2 standard drinks (14 g of pure ethanol) within 6 hours before and 6 hours after vitamin administration.\n9. Participants must agree to discontinue current vitamin\u002Fmineral supplements, including multivitamins, that contain Vitamin E (α-tocopherol) or CoQ10 (ubidecarenone) and abstain from taking these supplements while on study, including during the follow-up period. Participants must also agree to discontinue and abstain from high-dose vitamin\u002Fmineral supplementation while on-study and during the study follow-up period. NOTE: Participants for whom high-dose vitamin\u002Fmineral supplementation is medically necessary are eligible if the principal investigator determines that continuing treatment will not impact safety or study outcomes.\n10. Women of childbearing potential and male participants with partners of childbearing potential must agree to use two forms of medically effective contraception (at least one of which must be a barrier method) while on study until one month following the last dose of vitamin supplements.\n11. As determined by the enrolling physician, the participant must be able to understand and comply with study procedures for the entire length of the study. There must not be psychological, familial, sociological, or geographical conditions potentially hampering protocol compliance, including alcohol dependence or drug abuse.\n12. The participant or the participant's legally authorized representative must provide documented informed consent after being informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts.\n13. Participant must have adequate hematological, organ, and clotting function as defined below. Screening labs must be obtained prior to the end of radiation therapy.\n\n    * Absolute Neutrophil Count (ANC) ≥ 500\u002Fmm3\n    * Platelets ≥ 50,000\u002Fmm3 • Hemoglobin ≥ 8.0 g\u002FdL. The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002FdL is acceptable.\n    * Calculated creatinine clearance (CrCl (mL\u002Fmin); Cockcroft-Gault formula) ≥ 30 mL\u002Fmin.\n    * Total bilirubin ≤ 1.5X institutional upper limit of normal (ULN) or ≤3 X ULN for patients with known Gilbert's syndrome\n    * AST (SGOT) and ALT (SGPT) ≤ 3X institutional ULN\n    * PT\u002FINR and PTT (in the absence of lupus anticoagulant) ≤ 2X institutional ULN.\n\nExclusion Criteria:\n\n1. Participants who do not receive ≥ 80% of the planned total radiation.\n2. Participants who are scheduled to receive SBRT\u002FSRS\n3. Participant's treatment plan must not include anti-cancer pharmaceutical therapies during the period of vitamin administration (\\~3 months after completion of radiation therapy).\n4. Participants must not receive any other investigational agents while on study.\n5. Participants must not have contraindications to Vitamin E or CoQ10 supplementation, including:\n\n   1. Anticoagulation or antiplatelet therapy that cannot be stopped. NOTE: To be eligible, participants must be able to discontinue contraindicated medications at least 2 weeks prior to the initiation of study treatment. These medications may be resumed 1 month after completing study treatment.\n   2. Underlying bleeding conditions (e.g., hemophilia or von Willebrand disease)\n   3. Retinitis pigmentosa\n   4. Hepatobiliary dysfunction\n   5. Vitamin K deficiency\n   6. Preexisting severe fibrosis\n   7. History of significant cerebrovascular disease\u002Fevent, including stroke or intracranial hemorrhage.\n   8. Uncontrolled Grade 2 hypertension defined as ≥ 140 mm Hg systolic blood pressure or ≥ 90 mm Hg diastolic blood pressure.\n   9. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenia purpura).\n   10. Uncontrolled systemic bacterial, fungal, parasitic, mycobacterial, viral, or other infections, despite appropriate antibiotics or other treatments.\n   11. Any other uncontrolled comorbidities that, in the opinion of the treating investigator, would compromise subject safety or study outcomes.\n6. Participant must not have a history of allergic reactions to Vitamin E or CoQ10 or any of the vitamin excipients (soybean oil, soy lecithin, gelatin, glycerin).\n7. Not pregnant or lactating. A negative pregnancy test (serum hCG) is required for participants of childbearing potential. Female participants who are permanently sterilized (hysterectomy\u002Fbilateral oophorectomy) or postmenopausal (12 months of consecutive amenorrhea, \\> 45 years-of-age in the absence of other biological or physiological causes; females \\\u003C 55 years-of-age with serum FSH level \\> 40 mIU\u002FmL) are exempt","ALL","19 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this supportive care study is to learn if high-dose Vitamin E and CoQ10 in combination can reduce the negative sub-acute and chronic side effects of radiation to the pelvis in adults treated for prostate, uterine, cervical, or anal cancer.\n\nThe main questions it aims to answer are:\n\n* Is taking high doses of Vitamin E (dl-α-tocopherol acetate, 900mg) and CoQ10 (ubidecarenone, 200 mg) each day safe and tolerable?\n* Does a 90-day course of vitamin supplementation with high-dose Vitamin E and CoQ10 reduce the incidence and severity of late radiation-associated toxicities?\n* Does high-dose vitamin supplementation with Vitamin E and CoQ10 improve patient reported measure of quality of life?\n* Does high-dose vitamin supplementation with Vitamin E and CoQ10 change the trajectory of recovery after radiation therapy?\n* Is there evidence that suggests high-dose vitamin supplementation with Vitamin E and CoQ10 impairs oncologic outcomes?\n* Can longitudinal biomarkers of oxidative stress be correlated with Vitamin E and CoQ10 concentrations or radiation-associated toxicity?\n* Will subjects adhere to the vitamin administration schedule?\n* Are there demographic differences in systemic exposure to the vitamins?\n* Are there differences in toxicity outcomes across tumor types or radiation dose fractionation schemes?\n\nParticipants will be asked to:\n\n* Take Vitamin E and CoQ10 every day for 90 days by mouth.\n* Fill out quality of life questionnaires to assess treatment impacts.\n* Come for clinic visits every 2-4 weeks for around 4 months, then every 3-6 months for around 2 years.\n* Have blood draws more frequently than standard-of-care for clinical laboratory examinations and the collection of research samples.\n* Undergo Computed Tomography (CT) imaging of the chest, abdomen, and pelvis more frequently than standard of care.\n* Agree to lifestyle changes that ensure adequate vitamin absorption including intermittent abstinence from alcoholic beverages.",[27,28,29,30],"Prostate Cancer","Uterine Cancer","Cervical Cancer","Anal Cancer",[32,33,34,35],"radiation","toxicity","subacute","antioxidant","NOT_YET_RECRUITING","2026-06-19",{"date":39,"type":40},"2026-06-25","ACTUAL",{"date":42,"type":20},"2026-07-01",{"date":44,"type":20},"2030-12-15",{"name":46,"class":47},"University of Nebraska","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100556596","investigations-of-reproductive-cancers-in-women-100556596","NCT06527157","Investigations of Reproductive Cancers in Women","PROspective ACcrual To Investigate reprOductive Cancers in womeN","PROACTION:","Inclusion Criteria:\n\n1. Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study.\n2. Willing and able to comply with scheduled visits, study plan, and other procedures.\n3. Expected to be available for the duration of the study and can be contacted by telephone during study participation.\n4. Females aged 45 and older (with roughly 80% of enrolled subjects over the age of 50).\n5. Presence of uterus.\n6. AUB or PMB being worked up to diagnose the cause of the bleeding\n\nExclusion Criteria:\n\n1. Investigator site staff members directly involved in the conduct of the study and their family members or subjects who are PinkDx, Inc. employees or their family members.\n2. Other medical or psychiatric conditions that would increase the risk of study participation in the judgement of the Investigator.\n3. Women who have had a hysterectomy.\n4. Women with a known history of endometrial cancer or uterine sarcoma.\n5. Women who have received prior treatment for endometrial cancer.\n6. Inability or unwillingness to sign informed consent.\n7. Clinical suspicion of pregnancy.\n8. Women who have used a tampon within 7 days of sample collection.","FEMALE","45 Years","100 Years",{"count":61,"type":20},4500,"OBSERVATIONAL","The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.",[28],"RECRUITING","2026-06-17",{"date":68,"type":40},"2026-06-18",{"date":70,"type":40},"2024-07-30",{"date":72,"type":20},"2031-11-15",{"name":74,"class":75},"PinkDx, Inc.","INDUSTRY",16,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100497549","phase-2-proton-therapy-for-post-surgical-treatment-of-gynecologic-cancer-100497549","NCT05758688","PROton Therapy for Post Surgical Treatment of GYNecologic Cancer","Adjuvant Proton Whole Pelvis Radiation Therapy for Treatment of Post-Surgical Gynecologic Cancers","PROPS GYN","Inclusion Criteria:\n\n* Histologically confirmed cervical or endometrial cancer\n* Indication for adjuvant whole pelvic radiation therapy, with or without systemic therapy\n* Age of 18 years or older\n* Written informed consent\n* ECOG of 0-2 within 3 months of enrolling\n\nExclusion Criteria:\n\n* Prior course of pelvic radiation\n* Metastatic disease outside of the pelvis\n* Active inflammatory bowel disease\n* Incapacity to provide informed consent","18 Years",{"count":5,"type":20},[24],"This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.",[29,28,90],"Endometrial Cancer","2026-06-09",{"date":93,"type":40},"2026-06-10",{"date":95,"type":40},"2023-11-06",{"date":97,"type":20},"2026-12",{"name":99,"class":47},"Abramson Cancer Center at Penn Medicine",3,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":48},"100509651","phase-2-18ffes-petct-in-uterine-cancer-100509651","NCT05916196","[18F]FES PET\u002F.CT in Uterine Cancer","[18F]FLUOROESTRADIOL (FES) PET\u002FCT IMAGING OF THE ESTROGEN RECEPTOR IN PATIENTS WITH METASTATIC OR RECURRENT UTERINE CANCER","Inclusion Criteria\n\n1. Participants will be ≥ 18 years of age\n2. Recurrent or metastatic or intact non-operated uterine cancer not treated with surgery that is biopsy-proven or demonstrated on other standard of care imaging (e.g. CT, FDG PET\u002FCT, MRI, bone scan, x-ray, ultrasound)\n3. At least one lesion outside the liver detected by standard of care imaging (e.g.CT, FDG PET\u002FCT, MRI, bone scan, x-ray, ultrasound)\n4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n5. Subjects that are currently on or have recently discontinued tamoxifen or fulvestrant would require an 8-week or 28-week, respectively, washout period prior to FES PET\u002FCT scan.\n\nExclusion Criteria\n\n1. Females who report they are pregnant at screening will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential prior to FES injection.\n2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study",{"count":109,"type":20},30,[24],"Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.\n\n\\[18F\\]fluoroestradiol (FES) PET\u002FCT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET\u002FCT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET\u002FCT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy). The selection of therapy will be made by a treating physician and will not be affected by participation in this imaging study. Results of the FES PET\u002FCT scan may be shared with the treating physician or subject by request but will not be used to make clinical decisions about treatment.",[28],[114],"estrogen receptor PET imaging","2026-06-04",{"date":117,"type":40},"2026-06-05",{"date":119,"type":40},"2024-04-05",{"date":121,"type":20},"2028-08-01",{"name":99,"class":47},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":133,"conditions":134,"keywords":140,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100517943","performance-of-symmcora-vs-v-loc-suture-material-in-patients-undergoing-laparoscopic-total-hysterectomy-100517943","NCT06024109","Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy","Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy","BARHYSTER","Inclusion Criteria:\n\n* Females undergoing an elective, laparoscopic total hysterectomy\n* Age ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Open surgery\n* Patients undergone immunosuppressive drug treatment within the prior 6 months\n* Patients with hypersensitivity or allergy to the suture material.\n* Participation in another clinical study\n* Non-compliance of patient",{"count":132,"type":20},132,"The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate.\n\nSecondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.",[135,136,137,28,138,139,29,90],"Abnormal Uterine Bleeding","Endometriosis","Uterine Prolapse","Ovarian Cancer","Fallopian Tube Cancer",[141,142,143,144],"Barbed Suture","Hysterectomy","Laparoscopy","Minimal Invasive","2026-06-01",{"date":147,"type":40},"2026-06-02",{"date":149,"type":40},"2024-03-19",{"date":151,"type":20},"2027-08",{"name":153,"class":75},"Aesculap AG",2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":180,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100483771","phase-1-rinatabart-sesutecan-rina-s-pro1184-gen1184-for-advanced-solid-tumors-gct1184-01-pro1184-001-100483771","NCT05579366","Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01\u002F PRO1184-001)","Phase 1\u002F2 Study of Rina-S in Patients With Locally Advanced and\u002For Metastatic Solid Tumors","RAINFOL-01","Inclusion Criteria:\n\nPart A and B:\n\n* Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).\n* Previously received therapies known to confer clinical benefit.\n* Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.\n\nPart C, E, and H:\n\nParticipants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.\n\n* High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)\n* Participants must have received up to 3 prior lines of therapy. Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.\n* Participants must have platinum-resistant ovarian cancer.\n* Participants must have received prior bevacizumab or approved biosimilar.\n* Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration \\[FDA\\]-approved test in a Clinical Laboratory Improvement Amendments \\[CLIA\\]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.\n* Measurable disease per the RECIST v1.1 at baseline.\n\nPart D:\n\nCohort D1:\n\n* Participants must have platinum-sensitive ovarian cancer.\n* Participants must have received 1 to 3 prior lines of therapy.\n\nCohort D2:\n\n* Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.\n* Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.\n* Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.\n\n  * Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (\\>183 days) or more from the last dose of platinum-based therapy.\n\nCohort D3:\n\n• Endometrial cancer (any subtype excluding sarcoma).\n\nCohort D4:\n\n• Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).\n\nPart F and G:\n\n* Participants must have histologically or cytologically confirmed EC.\n* Recurrent progressive EC (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.\n* Participants must have received 1 to 3 prior lines of therapy, and must have progressed radiographically on or after their most recent line of therapy:\n* Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-\\[L\\])1 inhibitor.\n* Participants who progress \\>12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.\n* Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart I:\n\n* Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer (excluding clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies or low grade\u002Fborderline ovarian tumors).\n* Participants must have platinum sensitive ovarian cancer.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart J:\n\n* Participants must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart K:\n\n* Participants must have histologically or cytologically confirmed metastatic or unresectable ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element).\n* Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nExclusion Criteria:\n\n* History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids within the past 2 years, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.\n\nNote: Other protocol-defined inclusion\u002Fexclusion may apply.",{"count":164,"type":20},884,[23,24],"This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.\n\nParticipants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).",[168,169,170,139,90,171,172,173,174,175,176,177,178,179,28],"High Grade Epithelial Ovarian Cancer","High Grade Serous Ovarian Cancer","Primary Peritoneal Carcinoma","Non-small Cell Lung Cancer","Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)","Mesothelioma","Breast Adenocarcinoma","Triple Negative Breast Cancer","Hormone Receptor-positive\u002FHer2 Negative Breast Cancer","Platinum-resistant Ovarian Cancer (PROC)","Platinum Sensitive Ovarian Cancer (PSOC)","Primary Refractory Ovarian Cancer",[181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],"antibody-drug conjugate","folate receptor alpha","folate receptor","solid tumor","ovarian cancer","primary peritoneal carcinoma","fallopian tube cancer","endometrial cancer","non-small cell lung cancer","mesothelioma","breast cancer","triple negative breast cancer","hormone receptor-positive (HR+)\u002Fhuman epidermal growth factor receptor 2 negative (HER2-) breast cancer","topoisomerase I inhibitor","PROC","epidermal growth factor receptor (EGFR)-mutated NSCLC",{"date":198,"type":40},"2026-06-03",{"date":200,"type":40},"2022-12-07",{"date":202,"type":20},"2027-10",{"name":204,"class":75},"Genmab",66,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":57,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":218,"conditions":219,"keywords":224,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":48},"100496383","physical-activity-intervention-among-older-women-with-gynecologic-cancers-fit4treatment-100496383","NCT05743517","Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)","Patient-Tailored Physical Activity Intervention Among Older Women With Gynecologic Cancers Undergoing Chemotherapy (Fit4Treatment)","Inclusion Criteria:\n\n* Female; \\> 60 years of age\n* Diagnosis of endometrial\u002Futerine, ovarian, cervical or vulvar\u002Fvaginal cancer\n* Undergoing or planning to undergo any systemic treatment for a gynecologic malignancy (e.g., chemotherapy, immunotherapy, anti-angiogenic therapies, targeted therapies, etc.)\n* Willing to try to identify an exercise partner to participate with them, if needed\n* Fluent in English\n\nExclusion Criteria:\n\n* Uncontrolled cardiovascular disease or other major contraindications to physical activity\n* Active brain metastases\n* Cognitive or functional limitations that preclude a patient's ability to participate in the physical activity intervention\n* Pregnant women or prisoners","60 Years",{"count":215,"type":20},192,[217],"NA","The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific survival.",[220,90,28,29,221,222,223],"Ovary Cancer","Cervix Cancer","Vulvar Cancer","Vaginal Cancer",[225,226,227,228,229,230],"behavioral intervention","physical activity","cancer outcomes","chemotherapy","systemic therapy","quality of life","2026-05-27",{"date":233,"type":40},"2026-05-29",{"date":235,"type":40},"2023-09-15",{"date":237,"type":20},"2029-08-01",{"name":239,"class":47},"Northwestern University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":57,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":251,"conditions":252,"keywords":259,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":48},"100640491","measurement-of-urinary-hormones-in-patients-with-abnormal-uterine-bleeding-to-study-uterine-cancer-progression-100640491","NCT07581288","Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression","Quantitative Hormonal Biomarkers of Uterine Cancer Progression in Patients With Abnormal Uterine Bleeding","MIRA","Inclusion Criteria:\n\n* 35 years and older\n* Have experienced AUB\n\nExclusion Criteria:\n\n* Currently pregnant or become pregnant during their participation\n* Previous surgeries impairing the menstrual cycle (e.g. hysterectomy, bilateral oophorectomy)\n* Currently or in the previous 3 months on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, hormone replacement, etc.)","35 Years",{"count":250,"type":20},50,"The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor. The investigators will measure recruitment rate, attrition and cycle collection completeness of data. The investigators will evaluate menstrual health literacy at baseline and at the conclusion of the study.",[253,28,254,90,255,256,257,258],"Uterine Bleeding","Uterine Neoplasms","Endometrial Hyperplasia","Endometrial Intraepithelial Neoplasia","Menstrual Cycle","Reproductive Endocrinology",[260,261,28,135,262,263,264,265,266,267],"Digital Health","Urinary Hormones","Menstrual Cycle Tracking","At-home monitoring","Follicle Stimulating Hormone","Luteinizing Hormone","Estrogen","Progesterone","2026-05-06",{"date":270,"type":40},"2026-05-12",{"date":272,"type":20},"2026-05",{"date":274,"type":20},"2026-09",{"name":276,"class":47},"University of British Columbia",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":294,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100634670","phase-1-a-study-to-investigate-the-safety-and-efficacy-of-kqb368-as-monotherapy-in-participants-with-advanced-solid-malignancies-100634670","NCT07542704","A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies","A Phase 1\u002F1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB368 in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations","* Histologically confirmed diagnosis of a solid tumor\n* Malignancy with either a KRAS G12C or KRAS G12S mutation\n* Unresectable or metastatic disease\n* No available treatment with curative intent\n* Adequate organ function\n* Measurable disease per RECIST v1.1\n* Must be able to swallow with no GI condition that prevents absorption",{"count":285,"type":20},48,[23],"The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are:\n\n* What is the safe dose of KQB368 as a monotherapy?\n* Does KQB368 decrease the size of the tumor?\n* What happens to KQB368 in the body?\n\nParticipants will:\n\n* Take KQB368 orally daily in 21-day cycles\n* Return to the study site about 7 times in the first 5 weeks, and then once at the beginning of every 21-day cycle after that",[289,290,291,28,292,293],"Advanced Solid Tumors","Colorectal Cancer (CRC)","Non-Small Cell Lung Cancer","KRAS G12C Mutations","KRAS G12S Mutations",[295],"KQB368","2026-04-17",{"date":298,"type":40},"2026-04-21",{"date":272,"type":20},{"date":301,"type":20},"2029-12",{"name":303,"class":75},"Kumquat Biosciences Inc.",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":21,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":48},"100482273","phase-1-cabozantinib-and-dostarlimab-in-recurrent-gynecologic-carcinosarcoma-100482273","NCT05559879","Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma","A Phase Ib\u002FII Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of carcinosarcoma (independent of organ of gynecologic origin)\n2. Received at least one prior chemotherapy regimen for their cancer\n3. Must have measurable or evaluable lesion defined by iRECIST\n4. Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy\n5. ECOG Performance Status of 0-2\n6. Age ≥ 18 years\n7. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3 (≥ 1.5 GI\u002FL) without granulocyte colony-stimulating factor support.\n   2. White blood cell count ≥ 2500\u002Fmm3 (≥ 2.5 GI\u002FL).\n   3. Platelets ≥ 100,000\u002Fmm3 (≥ 100 GI\u002FL) without transfusion.\n   4. Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.\n   6. Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN).\n   7. Serum albumin ≥ 2.8 g\u002Fdl.\n   8. Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL\u002Fmin (≥ 0.5 mL\u002Fsec) using the Cockcroft-Gault equation:\n\n   \\[(140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\\] × 0.85 i. Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol).\n8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n9. Women of childbearing potential (WOCBP) ie. sexually active fertile patients and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment.\n10. Females should not breastfeed while receiving treatment on trial.\n11. Female patients of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, with the exception of those who had a prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression, or other reasons.\n\nExclusion Criteria:\n\n1. Prior treatment with cabozantinib.\n2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives (whichever is longer) before first dose of study treatment.\n3. Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n4. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Patients with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible patients must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n6. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixabin, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n7. The patient has prothrombin time (PT)\u002FINR or partial thromboplastin time (PTT) test ≥ 1.3 X the laboratory ULN within 7 days before the first dose of study treatment.\n8. The patient has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n\n   ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\n   iii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose.\n\n   b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. The patient has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\n   ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.\n\n   Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.\n\n   c. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose.\n\n   d. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n\n   e. Lesions invading or encasing any major blood vessels. f. Other clinically significant disorders that would preclude safe study participation.\n\n   i. Serious non-healing wound\u002Fulcer\u002Fbone fracture ii. Uncompensated\u002Fsymptomatic hypothyroidism (i.e. inadequately treated hypothyroidism) iii. Moderate to severe hepatic impairment (Child-Pugh B or C)\n9. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n10. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment \\[add reference for Fridericia formula\\].\n\n    Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n11. Inability to swallow tablets.\n12. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n13. Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.\n14. Patients with concurrent cytotoxic chemotherapy or radiation therapy are excluded.\n15. Patients with a serious chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.\n16. Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.\n17. Presence of a known active acute or chronic infection including: a urinary tract infection, HIV or viral hepatitis; however, it is acceptable to treat an acute infection and then re-screen or re-evaluate eligibility.\n18. Administration of a live, attenuated vaccine within 30 days prior to first dose of study treatment\n19. Other clinically significant disorders:\n\n    1. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n    2. Active, known, or suspected autoimmune disease (exceptions: type 1 diabetes mellitus, hypothyroidism, skin disorders, conditions not expected to recur in the absence of an external trigger)\n    3. Malabsorption syndrome\n    4. Requirement for hemodialysis or peritoneal dialysis\n    5. History of solid organ or allogenic stem cell transplant",{"count":312,"type":20},37,[23,24],"Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as a combination to patients with recurrent gynecologic carcinosarcoma.",[316,317,28,90],"Gynecologic Cancer","Carcinoma",[316,317,28,90],"2026-04-10",{"date":321,"type":40},"2026-04-15",{"date":323,"type":40},"2023-08-20",{"date":325,"type":20},"2027-04",{"name":327,"class":47},"University of Alabama at Birmingham",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":336,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":339,"conditions":340,"keywords":347,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":48},"100550437","cancer-loyalty-card-study-2-clocs-2-100550437","NCT06447064","Cancer Loyalty Card Study 2 (CLOCS-2)","Cancer Loyalty Card Study 2: a Retrospective Observational Case-Control Study","(CLOCS-2)","Inclusion Criteria (ALL):\n\n* Individuals aged \\>18 years of age\n* Individuals must be residing in the United Kingdom at the time of giving informed consent\n* Individuals must be registered with an NHS GP Practice\n* Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer).\n* Individuals must be a primary registered cardholder\\* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team\n* Tesco Clubcard\n* Boots Advantage Card\n* Provision of written informed consent\n* Willing and able to comply with all required study activities\n\n  * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study.\n\nExclusion Criteria (ALL):\n\n* Individuals under the age of 18 years\n* Non-UK residents, at the time of giving informed consent\n* Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card\n* Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and\u002For where the primary registered cardholder does not make purchases for or on behalf of the individual\n\nExclusion Criteria (CASES):\n\n• Individuals will not be able to join as a case if:\n\n* they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer).\n* they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer).\n\nExclusion Criteria (Controls):\n\n• Individuals will not be able to join as a control (Group 2) if:\n\no they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer).",true,{"count":338,"type":20},2900,"Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.\n\nTherefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.\n\nThe major reasons for not presenting to the GP with symptoms such as these are \"not wanting to waste the GP's time\" and normalisation of these symptoms.\n\nThe persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.\n\nRATIONALE FOR CURRENT STUDY\n\nAn early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.\n\nInformation about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.",[341,342,343,344,345,346,28,222,138,90],"Pancreatic Cancer","Colon Cancer","Oesophageal Cancer","Stomach Cancer","Liver Cancer","Bladder Cancer",[138,348,349,350],"Epidemiology","Observational Study","Risk Assessment","2026-03-24",{"date":353,"type":40},"2026-03-25",{"date":355,"type":40},"2026-02-04",{"date":325,"type":20},{"name":358,"class":47},"Imperial College London",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":21,"phases":368,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":48},"100515355","alternate-day-fasting-after-surgery-for-patients-undergoing-chemotherapy-100515355","NCT05990426","Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy","The Impact of Alternate Day Fasting After Surgery for Patients Undergoing chemoTherapy (FAST Study)","FAST","Inclusion Criteria:\n\n1. Female; ≥ 18 years of age\n2. Confirmed or high suspicion for endometrial, ovarian, fallopian tube or primary peritoneal cancer, and are able and expecting to undergo adjuvant chemotherapy following hysterectomy for treatment of disease, as determined by their treating physician\n3. Fluent in spoken and written English\n4. Own a smart phone\n5. Have access to the internet to complete surveys\n6. ECOG status of 0 or 1\n7. Willingness to sign informed consent form\n\nExclusion Criteria:\n\n1. Patients who are not planning to undergo chemotherapy at Northwestern Medicine\n2. Patients engaged in shift work (i.e., those who work nights, 3rd shift)\n3. BMI of 50+ or those with a diagnosed eating disorder. Patients who take medications for blood glucose regulation (e.g. insulin), and\u002For require treatment with therapeutic doses of anticoagulants will be excluded.\n4. Patients who have been diagnosed with medication-dependent diabetes, recent myocardial infarction, stroke, pulmonary embolus, renal failure, or any condition that may preclude ability to tolerate a short-term fast will be excluded.\n5. Patients who take medications where conditions may be influenced in the presence of fasting (e.g. hypertension, electrolyte abnormalities, migraines) will be monitored by their treating physician for any necessary adjustments in these medications.\n6. Patients whose oncologist has not provided clearance for their participation\n7. Unable or unwilling to follow a diet regimen or participate in ketone measurements\n8. ECOG status greater than 1\n9. Patients who have undergone prior systemic therapy to treat a malignancy in the last 2 years.",{"count":109,"type":20},[217],"Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously shown to be safe. There is no data specifically addressing the impact of a fasting diet regimen on side effects of chemotherapy during treatment for ovarian and endometrial cancers in the front-line setting. The information gathered from this study will inform future trials about the role of time-restricted eating and its impact on side-effects associated with chemotherapy as well as its role in improvement of quality of life for women afflicted with these debilitating diseases.",[220,90,28],[228,372,373],"peripheral neuropathy","intermittent fasting","2026-03-20",{"date":351,"type":40},{"date":377,"type":40},"2023-10-16",{"date":379,"type":20},"2026-08",{"name":239,"class":47},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":21,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":48},"100365466","phase-1-fecal-microbiota-transplantation-in-treating-immune-checkpoint-inhibitor-induced-diarrhea-or-colitis-in-genitourinary-cancer-patients-100365466","NCT04038619","Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients","Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea\u002FColitis in Genitourinary Cancer Patients","Inclusion Criteria:\n\n1. Diagnosis of any type of genitourinary (kidney, bladder and prostate), melanoma, non-melanoma skin cancer, lung, head \\& neck, sarcoma\u002Flymphoma, gastrointestinal system (luminal GI, hepatobiliary, pancreas), gynecology system (ovarian, uterine, cervical), and breast malignancies\n2. Treatment with any ICPI agent(s)\n3. Participants with new onset of ≥ grade 2 ICPI-induced diarrhea and\u002For colitis symptoms based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5 within 45 days prior to date of FMT treatment without involvement of non- GI toxicity\n4. Participants with a history of steroid use before FMT can be allowed if last dose was \\> 30 days prior to FMT treatment or treatment duration was for \\\u003C7 days beyond one week prior to FMT treatment\n5. Participants with a history of immunosuppressant (Infliximab, Vedolizumab etc) use before FMT can be allowed if last dose was administered ≥ 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., Infliximab is used in the treatment of Crohn's disease, rheumatoid arthritis, plaque psoriasis, and Vedolizumab is used in treating ulcerative colitis)\n6. No concern for active concomitant GI infection at the time of initiation of protocol therapy as confirmed by stool tests or as per the treating physician based on clinical presentation\n7. Patient has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g., lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of protocol therapy and\u002F or imaging (e.g. CXR, CT CAP etc) confirms the absence of active infections (e.g. TB) within 60 days prior to initiation of protocol therapy\n8. Ability to understand and willingness to sign an informed consent form\n9. Life expectancy \\> 6 months\n\nExclusion Criteria\n\n1. Age younger than 18 years\n2. Participants with persistent GI infection confirmed with positive stool test(s) despite completing 5 days of antibiotics prior to initiation of protocol therapy\n3. History of inflammatory bowel disease, and\u002For radiation enteritis or colitis with active disease status at the time of study treatment initiation\n4. Pregnant and breastfeeding women\n5. Women who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \\> 1 year prior to consent and\u002F or clear documentation states that participant is peri- or post-menopausal or there has been recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment\n6. Immunosuppressive treatment at onset of ICPI-induced diarrhea\u002Fcolitis\n7. Any medical conditions (e.g. severe heart failure, brain hemorrhage, septic shock, etc.) that are high risk for colonoscopy procedure by the assessment of the study PI or Co-PIs.\n8. Participants who develop concurrent non-GI toxicity at the time of study treatment\n9. Donors at risk for monkeypox infection and\u002F or exposure as determined by a questionnaire",{"count":389,"type":20},40,[23],"This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea\u002Fcolitis.",[393,394,395,396,397,138,28,398,29],"Colitis","Diarrhea","Malignant Genitourinary System Neoplasm","Melanoma","Lung Cancer","Breast Cancer","2026-03-17",{"date":374,"type":40},{"date":402,"type":40},"2021-02-01",{"date":404,"type":20},"2027-12-31",{"name":406,"class":47},"M.D. Anderson Cancer Center",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":48},"100514371","trans-rectal-ultrasound-of-the-female-pelvis-for-real-time-mri-us-fusion-based-needle-tracking-100514371","NCT05977621","Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking","Acquisition of Trans-Rectal Ultrasound [TRUS] Images of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking for Image-Guided Brachytherapy: A Pre-feasibility Study","(TRUS)","Inclusion Criteria:\n\n* Histologically proven invasive primary squamous, adenosquamous, or adenocarcinoma of the uterine cervix, (recurrent or medically inoperable) uterine adenocarcinoma.\n* Treatment plan must include curative-intent definitive radiation that includes brachytherapy treatments with or without concurrent chemotherapy\n* Adults ≥ 18 years of age\n* ECOG Performance Status 0-2\n\nExclusion Criteria:\n\n* Patients with active rectal bleeding or rectal ulcer","90 Years",{"count":417,"type":20},17,"The purpose of this study is to utilize transrectal ultrasound (TRUS) images of the intact and post-hysterectomy female pelvis in order to provide feasibility information for a Magnetic Resonance Imaging (MRI)-TRUS fusion based 3D needle navigation system for use in image guided brachytherapy. The fusion and needle guidance will be performed using Eigen Health's navigation system that currently provides targeted MR\u002FUltrasound fusion based prostate biopsies utilizing a proprietary 3D semi-robotic navigation system.",[28],"2026-03-04",{"date":422,"type":40},"2026-03-06",{"date":424,"type":40},"2024-02-07",{"date":426,"type":20},"2027-03",{"name":428,"class":47},"Duke University",{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":21,"phases":437,"briefSummary":438,"conditions":439,"keywords":442,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":154},"100544459","phase-2-azenosertib-in-uterine-serous-carcinoma-biomarker-study-100544459","NCT06369155","Azenosertib in Uterine Serous Carcinoma: Biomarker Study","A Biomarker Study of the Wee1 Inhibitor Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed recurrent or persistent uterine serous carcinoma. For the purposes of this study, uterine carcinomas (with the exception of carcinosarcomas) that have any component that is considered serous will be considered a uterine serous carcinoma.\n* Participants must have measurable disease, defined as at least one lesion that can be accurately measured per RECIST 1.1 criteria. See Section 12 for the evaluation of measurable disease.\n* Participants must have had one prior platinum-based chemotherapy regimen for management of advanced or metastatic uterine serous carcinoma. Participants with early stage disease who received adjuvant platinum-based chemotherapy are also eligible if they recur within 12 months of their adjuvant therapy. Chemotherapy administered only in conjunction with primary RT as a radiosensitizer should not count as a systemic regimen. There is no restriction on the number of prior lines of therapy a participant may have previously received. Additionally, participants must have a known tumor MSI or MMR status and those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy.\n* Age 18 years or older. Because no dosing or adverse event data are currently available on the use of azenosertib in participants \\\u003C18 years of age, children are excluded from this study.\n* ECOG performance status 0, 1, or 2 (see Appendix A)\n* Participants must meet the following organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1500\u002FmcL\n  * hemoglobin ≥9 g\u002FdL (must be at least 2 weeks since any blood transfusion)\n  * platelets ≥100,000\u002FmcL\n  * total bilirubin ≤ institutional upper limit of normal (ULN) or\n\n    ≤1.5x ULN in patients with liver metastases or well-documented Gilbert's Syndrome\n  * AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN or ≤5 × institutional ULN in patients with liver metastases\n  * creatinine ≤ 1.5x institutional ULN or estimated CrCl≥ 60 mL\u002Fmin\n* Willingness to release archival tissue for research purposes.\n* Biopsiable disease in a lesion that is not being utilized as the target lesion for RECIST assessment and willing to undergo pre- and on-treatment biopsies.\n* HIV-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. However, participants who are on antiretroviral therapy that includes strong inhibitors or inducers of CYP3A4 are not eligible, given the potential for interaction with azenosertib, which is a CYP3A4 substrate.\n* Participants with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression. Participants with new or progressive brain metastases (active brain metastases) are eligible only if the treating physician determines that immediate CNS-specific treatment is not required and is unlikely to be required during the first two cycles of therapy. Participants with known leptomeningeal disease are not eligible.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* The effects of azenosertib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had chemotherapy, radiotherapy, or investigational therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of azenosertib. Participants may not have had hormonal therapy within 2 weeks of the first dose of azenosertib.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy administered more than 3 weeks before first dose of azenosertib (e.g.,., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Participants who are receiving any other investigational agents for this condition.\n* Participants may not have had prior receipt of a cell cycle checkpoint inhibitor (e.g., Chek1, Wee1, or ATR inhibition)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to azenosertib.\n* Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine.\n* Pregnant women are excluded from this study because azenosertib is an DNA damage repair pathway agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with azenosertib, breastfeeding should be discontinued if the mother is treated with azenosertib.\n\n  --Women of childbearing potential (WoCBP) may be included only if acceptable contraception (see Appendix C) is in place for two weeks before study entry, for the duration of the treatment with the study drug and for 5x half-lives of ZN-c3 + 6 months after the last dose of ZN-c3. Sexually active female subjects of childbearing potential must agree to use protocol-recommended method of contraception from the start of the screening period until 6 months after the last dose of study drug ZN-c3.\n* Participants must not have undergone major surgical procedures within 28 days of beginning study treatment or minor surgical procedures within 7 days of beginning study treatment. Port-a-cath placement will be allowed within a 7 day window of starting study treatment.\n* Participants must be able to swallow oral medication and may not have refractory nausea and vomiting, have a percutaneous endoscopic gastrostomy (PEG) tube, be receiving total parenteral nutrition (TPN), or be dependent on IV fluid support.\n* Because the composition, PK, and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, cannabis, St. John's wort, kava, ephedra \\[ma huang\\], ginkgo biloba, dehydroepiandrosterone \\[DHEA\\], yohimbe, saw palmetto, and ginseng). Participants should stop herbal medications at least 7 days prior to first dose of azenosertib.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.",{"count":5,"type":20},[24],"This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma.\n\nThe name of the study drug involved in this study is:\n\n-Azenosertib (a type of Wee1 inhibitor)",[440,441,28],"Uterine Serous Carcinoma","Uterine Carcinoma",[440,441,28,443],"Persistent Uterine Serous Carcinoma","2026-02-27",{"date":446,"type":40},"2026-03-02",{"date":448,"type":40},"2025-03-05",{"date":450,"type":20},"2028-01-31",{"name":452,"class":47},"Joyce Liu, MD",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":463,"conditions":464,"keywords":469,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":48},"100617394","sample-collection-for-ongoing-research-and-product-evaluation-study-100617394","NCT07318051","Sample Collection for Ongoing Research and Product Evaluation Study","Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study","SCORE","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Any patient that has an untreated primary solid malignancy within the following cohorts:\n\n   1. Breast cancer\n   2. Lung cancer\n   3. Muscle invasive bladder cancer\n   4. Rectal cancer\n   5. Pancreatic cancer\n   6. Ovarian cancer\n   7. Gastroesophageal cancer\n   8. Prostate cancer\n   9. Melanoma\n   10. Hepatic\u002Fliver cancer\n   11. Uterine\u002Fendometrial cancer\n   12. Head and neck Cancer\n3. The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging.\n4. Eastern Cooperative Oncology Group performance status ≤ 2.\n5. Able to tolerate venipuncture for research blood draw(s).\n6. Consent to provide residual tumor tissue for research.\n7. Willing and able to comply with the study requirements.\n8. Signed informed consent(s) must be obtained prior to participation in the study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding.\n2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers.\n3. Has initiated postoperative systemic treatment.\n4. At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection.\n5. History of bone marrow or organ transplant.\n6. Serious medical conditions that may adversely affect ability to participate in the study.",{"count":462,"type":20},9600,"The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.",[398,397,465,466,341,138,467,27,396,468,28,345],"Muscle Invasive Bladder Cancer","Rectal Cancer","Gastroesophageal Cancer","Head and Neck Cancer",[470,471,472,473,474,475,476,477,396,478,479,480],"Breast cancer","Lung cancer","Muscle invasive bladder cancer","Rectal cancer","Pancreatic cancer","Ovarian cancer","Gastroesophageal cancer","Prostate cancer","Head and Neck cancer","Uterine cancer","Liver cancer","2026-01-13",{"date":483,"type":40},"2026-01-15",{"date":485,"type":40},"2025-07-21",{"date":487,"type":20},"2035-01",{"name":489,"class":75},"Natera, Inc.",{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":501,"conditions":502,"keywords":503,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":48},"100577540","prognostic-role-of-molecular-classification-in-fertility-sparing-treatment-of-endometrial-cancer-100577540","NCT06799624","Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr","Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr: PREFACE Study","PREFACE","Inclusion Criteria:\n\n1. Patients aged 18-45 years with a hysteroscopic confirmed diagnosis of endometrial cancer (FIGO stage IA without myometrial invasion, grade 1 or grade 2, endometrioid histology).\n2. Patients desiring fertility preservation\n3. Molecular classification of the tumor using next-generation sequencing (NGS) or Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE).\n4. Adequate pre-treatment imaging (MRI or transvaginal ultrasound) confirming no evidence of myometrial invasion or extrauterine spread.\n\nExclusion Criteria:\n\n1. Patients with atypical endometrial hyperplasia or intraepithelial neoplasia\n2. Individuals with tumor samples of insufficient quantity or inadequate quality were not included in the analysis\n3. Non-endometrioid histology.\n4. Patients with a history of prior uterine malignancy or current synchronous malignancies.\n5. Medical contraindications to hormonal therapy","50 Years",{"count":500,"type":20},100,"Endometrial cancer, the most common gynecologic malignancy in high-income countries, is increasing among reproductive-age women. While hysterectomy prevents pregnancy, hormonal therapies offer fertility-sparing options for select early-stage cases, with \\~80% achieving complete response (CR). Molecular classifications (POLEmut, p53abn, MMRd\u002FMSI-H, NSMP) reveal subtype-specific prognostic differences, with NSMP showing higher CR rates and lower recurrence, while p53abn and MMRd\u002FMSI-H fare worse. Recent studies emphasize molecular profiling's potential to guide personalized fertility-sparing treatments. This study explores the prognostic role of these classifications in treatment outcomes.",[28],[504,505,506],"uterine cancer","fertility-sparing","molecular classification","2025-12-16",{"date":509,"type":40},"2025-12-23",{"date":511,"type":20},"2026-01-01",{"date":450,"type":20},{"name":514,"class":47},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":59,"enrollmentInfo":522,"targetDuration":4,"studyType":21,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":48},"100285304","image-guided-gynecologic-brachytherapy-100285304","NCT02993900","Image-Guided Gynecologic Brachytherapy","A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed carcinoma. Central pathology review is not required; however, pathology will be reviewed at the SKCCC at Johns Hopkins.\n* Site\u002FStage\n* Any patient eligible for internal implantation without MR guidance will be considered eligible for this protocol. Standard criteria for internal implantation include:\n* Carcinoma of the cervix: Stage I-IVA or vaginal recurrence\n* Carcinoma of the uterus: Stage IIIB (vaginal involvement), inoperable, or vaginal recurrence\n* Carcinoma of the vagina: Stage I-IVA or vaginal recurrence\n* Carcinoma of the vulva: Stage I-IVA or recurrence\n* Carcinoma of the urethra based on treating physician's discretion\n* Patients who have received prior radiation or chemotherapy may be enrolled on this study.\n* Age \\> 18 years. Children do not develop these malignancies and therefore are not considered candidates for this trial.\n* Life expectancy of greater than 6 months.\n* ECOG performance status of \\\u003C2 or greater, based on treating physician's discretion\n* MRI of the pelvis or PET-CT within 4 months before registration\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Absolute neutrophil count \\\u003C 500 at the time of enrollment\n* A history of metal in the head or eyes",{"count":523,"type":20},54,[217],"This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The therapy takes place in the Department of Radiation Oncology at the Johns Hopkins SKCCC. The purpose of this study is to investigate the ability of MRI to successfully guide the placement of the brachytherapy applicator necessary to treat participants' gynecologic cancer. The Investigators want to see if the use of MRI will do a better job of assessing the tumor at the time of brachytherapy than the routinely used CT scan. The Investigators also want to determine if the use of MRI will enable doctors to reduce the radiation dose received by the body during the process of treating the tumor.",[29,28,223,222,346],{"date":528,"type":40},"2025-12-18",{"date":530,"type":40},"2016-12-15",{"date":532,"type":20},"2028-12",{"name":534,"class":47},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":21,"phases":544,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":561},"100577185","phase-1-zanzalintinib-in-combination-with-paclitaxel-in-recurrent-high-grade-uterine-cancer-100577185","NCT06795009","Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","Phase I\u002FIB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","Inclusion Criteria:\n\n* Diagnosis of recurrent, FIGO grade 3 endometrioid, serous, or mixed high grade uterine or endometrial cancer or uterine carcinosarcoma. Patients must have experienced either prior progression on a platinum-based therapy or intolerance to platinum. Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents.\n* 1-2 prior lines of anti-cancer therapy are allowed.\n* Subjects who have received prior treatment with trastuzumab, pembrolizumab, or dostarlimab can enroll in the study. Use of these agents together or as maintenance therapy is considered 1 regimen.\n* Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy (eg, physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy are permitted)\n* Patients must have disease that cannot be managed by local therapy targeted at the tumor site (i.e. surgery, radiation therapy).\n* Measurable disease by RECIST 1.1.\n* At least 18 years of age.\n* ECOG performance status ≤ 2.\n* Adequate bone marrow and organ function within 14 days prior to first dose of study treatment, as defined below:\n\n  * Absolute neutrophil count ≥ 1.5 K\u002Fcumm without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection.\n  * Platelets ≥ 100 K\u002Fcumm ) without transfusion within 2 weeks of screening laboratory sample collection.\n  * Hemoglobin ≥ 9.0 g\u002FdL without transfusion within 2 weeks prior to screening laboratory sample collection.\n  * Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease ≤ 3 x ULN).\n  * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x ULN. For subjects with documented bone metastasis ALP ≤ 5 x ULN. Serum creatinine \\\u003C 1.5 x ULN OR calculated or measured creatinine clearance ≥ 40 mL\u002Fmin (using Cockcroft-Gault equation)\n  * INR ≤ 1.5 x IULN\n  * aPTT ≤ 1.2 x IULN\n  * Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol) creatinine\n* Female subjects of child-bearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff. Should a patient become pregnant or suspect pregnancy while participating in this study, the treating physician must be informed immediately.\n* The effects of zanzalintinib on the developing human fetus are unknown. For this reason and because chemotherapeutic agents are known to be teratogenic, patients of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and through 186 days after last dose of zanzalintinib or paclitaxel for women of child-bearing potential (WOCBP). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Any prior treatment with zanzalintinib\n* A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease.\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment, or any prior treatment with any tyrosine kinase inhibitor (TKI) or any prior treatment with bevacizumab.\n* Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment.\n* Receipt of any other investigational agents or has received an investigational agent within 4 weeks of start of study treatment.\n* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed.\n* Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin inhibitors ) and platelet inhibitors (eg, clopidogrel).\n\n  * Allowed anticoagulants are the following:\n\n    * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n    * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.\n* Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n* The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Unstable or deteriorating cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association Class 3 or 4, class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes).\n    * Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant arterial thrombotic and\u002For ischemic event within 6 months before first dose of study treatment.\n    * Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before first dose of study treatment. Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Subjects who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n    * Prior history of myocarditis.\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n    * Tumors invading the GI-tract from external viscera\n    * Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n    * Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before first dose unless cause of obstruction is definitively managed and subject is asymptomatic\n    * Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n    * Known gastric or esophageal varices\n    * Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks\n    * If tolerating PO, small bowel obstruction may be considered with Investigator and Sponsor approval\n* Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n* Symptomatic cavitating pulmonary lesion(s) or endobronchial disease (asymptomatic or radiated lesions allowed).\n* Lesions invading major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n* Other clinically significant disorders that would preclude safe study participation.\n\n  * Active infection requiring systemic treatment. Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.\n  * Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness except for subjects meeting all of the following criteria: (1) on stable anti-retroviral therapy; (2) CD4+ T cell count ≥ 200\u002FµL; and (3) an undetectable viral load. Note: HIV testing will be performed at screening if and as required by local regulation. Note: To be eligible, participants taking CYP inhibitors (eg, zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose. Note: CD4+ T cell counts, and viral load are monitored per standard of care by the local health care provider.\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  * Malabsorption syndrome.\n  * Pharmacologically uncompensated, symptomatic hypothyroidism.\n  * Moderate to severe hepatic impairment (Child-Pugh B or C).\n  * Requirement for hemodialysis or peritoneal dialysis.\n  * History of solid organ or allogeneic stem cell transplant.\n* Major surgery within 8 weeks prior to first dose of study treatment. Prior laparoscopic surgeries (ie nephrectomy) within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 5 days before first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment. Note: Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per electrocardiogram (ECG) before first dose of study treatment. Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility.\n* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.\n* Pregnant or lactating females.\n* Inability to swallow tablets\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n* Another malignancy that requires active therapy and in the opinion of the Investigator would interfere with monitoring of radiologic assessments of response to Investigational Product, within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.\n* Other conditions, which in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study.",{"count":543,"type":20},36,[23],"The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.",[28,90],[548,549,550,551],"Recurrent endometrial cancer","AXL\u002FGAS6","p53 mutation","High risk","2025-12-05",{"date":554,"type":40},"2025-12-11",{"date":556,"type":40},"2025-10-17",{"date":558,"type":20},"2035-04-30",{"name":560,"class":47},"Washington University School of Medicine",4,{"id":563,"slug":564,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":336,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":571,"conditions":572,"keywords":584,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":48},"100339653","liquid-biopsy-evaluation-and-repository-development-at-princess-margaret-100339653","NCT03702309","Liquid Biopsy Evaluation and Repository Development at Princess Margaret","LIBERATE","Inclusion Criteria:\n\n1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and\u002For family history without known aberration).\n2. Patient must be ≥ 18 years old.\n3. All patients must have signed and dated an informed consent form for this LIBERATE study.\n4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.\n\nExclusion Criteria:\n\nNone",{"count":570,"type":20},2500,"The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples (\"liquid biopsies\") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.",[573,398,397,342,138,396,574,575,576,577,578,579,580,28,581,582,468,583],"Cancer","Lymphoma","Leukemia","Mutation","Lynch Syndrome","Cowden Syndrome","BRCA1 Mutation","BRCA2 Mutation","Myeloma","Kidney Cancer","Meningioma",[585,586,587,588,589,590,591,592],"High Risk","Liquid Biopsy","Circulating Tumor DNA","Blood","Molecular Profiling","Next Generation Sequencing","Solid Tumors","Hematological","2025-11-25",{"date":595,"type":40},"2025-11-26",{"date":597,"type":40},"2017-08-03",{"date":599,"type":20},"2026-07-06",{"name":601,"class":47},"University Health Network, Toronto",{"id":603,"slug":604,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":21,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":621,"locationsCount":48},"100596365","molecular-and-cellular-profiling-of-uterine-lavage-collected-during-gynecologic-surgery-100596365","NCT07044505","Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery","Exploring the Molecular and Cellular Composition of Uterine Lavage Specimens Collected at the Time of Gynecologic Surgery.","Inclusion Criteria:\n\n* Undergoing gynecologic surgery with Stanford Healthcare\n* Intact uterus and cervix\n* At least one intact fallopian tube and ovary (on the same side)\n* Aged 18 years or older\n* Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Known endometrial or cervical cancer or endometrial or cervical intraepithelial neoplasia\n* Status post bilateral salpingectomy or tubal ligation\n* Lack of consenting capacity\n* Positive preoperative pregnancy test\n* Active uterine bleeding (i.e. menses, etc.)\n* Intrauterine device in place\n* Non-English speaking (requires interpretor)",{"count":250,"type":20},[217],"This study is a designed as a to test the clinical and technical feasibility of using this novel uterine lavage collection catheter to collected UL samples from up to 50 individuals undergoing gynecologic surgery and to describe the cellular composition of these samples. In order to do this, it is a prospective consecutively-enrolled cohort of 50 participants, all of who will receive the intervention of uterine lavage collection.",[316,613,614,28],"Gynecologic Disease","Gynecological Surgery","2025-11-03",{"date":617,"type":40},"2025-11-05",{"date":619,"type":40},"2025-09-19",{"date":97,"type":20},{"name":622,"class":47},"Stanford University",{"id":624,"slug":625,"hasResults":11,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":11,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":21,"phases":632,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":154},"100568128","phase-2-belzutifan-in-recurrent-clear-cell-carcinoma-of-gynecologic-origin-100568128","NCT06677190","Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin","A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed recurrent or persistent clear cell carcinoma of the ovary (CCOC) or clear cell carcinoma of other gynecologic origin (e.g., endometrial, cervical, vaginal, vulvar, endometriosis-related). If mixed histology, then ≥50% clear cell component.\n* Participants must have measurable disease, defined as at least one lesion that can be accurately measured per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n* Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease.\n* Prior bevacizumab is allowed.\n* Prior use of immunotherapy is allowed.\n* Unlimited prior lines for the treatment of recurrent or persistent disease are allowed.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of Belzutifan in participants \\\u003C18 years of age, children are excluded from this study.\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 (Karnofsky performance scale ≥70%, see Appendix A).\n* Participants must meet the following organ and marrow function as defined below:\n\n  * Absolute neutrophil count ≥ 1,500\u002FmcL\n  * Hemoglobin ≥ 10.0 g\u002FdL (without use of erythropoietin; without packed red blood cell (RBC) transfusion within preceding 2 weeks)\n  * Platelets ≥ 100,000\u002FmcL\n  * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 ULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 × institutional upper limit of normal (ULN) (in the absence of liver metastases) or ≤ 5 x institutional ULN (in the presence of liver metastases)\n  * Creatinine ≤ 1.5 x institutional upper limit of normal (ULN) OR estimated creatinine clearance (CrCl) by the Cockcroft-Gault formula\n\n    ≥51mL\u002Fmin if creatinine \\> 1.5 x institutional ULN or institutional standard method\n  * INR OR PT and PTT ≤1.5 × institutional ULN unless participant is receiving anticoagulant therapy and PT\u002FINR or PTT are within therapeutic range of that anticoagulation\n* Participants with known brain metastases are eligible if they have completed primary CNS-directed therapy (such as surgical resection or radiotherapy) and if they have remained clinically stable, asymptomatic, radiologically stable without evidence of progression for at least 4 weeks by repeat imaging and have been off of steroids for at least 4 weeks prior to starting study treatment.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the Belzutifan, as determined after discussion with the Sponsor-Investigator, are eligible for this trial.\n* Archival tumor tissue must be available as 17 (15 unstained + 2 H\\&E) freshly serially cut slides from formalin-fixed, paraffin-embedded (FFPE) tissue blocks. The most recent available tissue is preferred to archived tissue. If fewer than 17 slides are available, the participant may still be eligible pending discussion with the Sponsor-Investigator.\n* The effects of Belzutifan on the developing human fetus are unknown. For this reason, women of child-bearing potential\\* must have a negative serum or urine pregnancy test at the Screening and Cycle 1 Day 1 visits. A negative serum or urine pregnancy test must be obtained within 24 hours before the first dose of study intervention in order to start receiving the study drug. Women of child-bearing potential and men must agree to use adequate contraception (see Appendix D) prior to study entry, for the duration of study participation, and for at least 30 days after last receipt of study therapy. Additionally, should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n\n  --Female participants who do not meet the definition of women of child-bearing potential must meet either criteria:\n  * Post-menopausal, defined as amenorrheic for at least 12 consecutive months within the appropriate age group and without an alternative medical cause OR\n  * Surgically sterilized (i.e. bilateral oophorectomy, bilateral tubal ligation or salpingectomy, or total hysterectomy)\n* Ability to swallow orally administered medications.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior use of Belzutifan or another HIF-2a inhibitor.\n* Participant has any of the following:\n\n  * Pulse oximeter reading \\\u003C92% at rest, or\n  * Requires intermittent supplemental oxygen, or\n  * Requires chronic supplemental oxygen\n* Anti-cancer treatment (chemotherapy, radiotherapy, or other investigational therapy) within 4 weeks prior to entering the study (6 weeks prior to study entry for nitrosoureas or mitomycin C).\n* Prior small molecule kinase inhibitor (including investigational kinase inhibitor) ≤ 2 weeks prior to entering the study.\n* Prior radiation therapy within 2 weeks of start of study drugs. Participants must have recovered from all radiation-related toxicities and must not require steroids. Participants must not have had radiation pneumonitis. Palliative radiation (≤2 weeks of radiotherapy) to non-CNS (central nervous system) disease is permitted, provided there is at least a 1-week washout prior to start of study drugs.\n* Use of herbal supplements, including but not limited to: cannabis, St. John's wort, gingko biloba, ginseng, saw palmetto, and ephedra. Herbal supplements must be stopped at least 1 week prior to beginning study treatment.\n* Participants who are known to require concomitant therapy with moderate or strong CYP3A4 inducers. Due to potential drug interactions, concomitant use of these medications is not permitted for the duration of treatment on trial. Participants are eligible for study entry if an appropriate substitution is made prior the first dose of study medication.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n* Participants who have AEs due to previous anticancer therapies must have recovered to\n\n  * Grade 1 or baseline with the exception of alopecia. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have\n  * Grade 2 neuropathy are eligible.\n* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines are allowed.\n\nNote: Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed in the study as long as they are mRNA vaccines, replication-incompetent adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.\n\n* Major surgical procedures within 4 weeks of beginning study treatment are not allowed. Minor surgical procedures (with the exception of port placement) within 1 week of beginning study treatment are not allowed.\n* Any gastrointestinal disorder that would interfere with the passage or absorption of oral medications. Participants must be able to swallow oral medications. Participants with an enteric tube (e.g., gastrostomy or jejunostomy tube), receiving total parenteral nutrition (TPN), or dependent on IV fluid support are ineligible.\n* Participants with significant cardiovascular impairment, including uncontrolled hypertension, congestive heart failure of New York Heart Association Grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia within the past 6 months.\n* Has moderate to severe hepatic impairment (Child-Pugh B or C).\n* Has received colony-stimulating factors (e.g., G-CSF, GM-CSF, or recombinant EPO)\n\n  ≤28 days prior to the first dose of study intervention.\n* Has a diagnosis of immunodeficiency.\n* Is known to be positive for Human Immunodeficiency Virus (HIV). Subjects with HIV, including those on antiretroviral therapy, are excluded due to risk of immunodeficiency and risk of overlapping toxicity.\n* Is known to be positive for Hepatitis B virus (HBV) or Hepatitis C virus (HCV). Participants are eligible if they have a history of HCV infection that has been treated and cured, with an undetectable viral load.\n* Participants with uncontrolled intercurrent illness, including but not limited to active infection and serious non-healing wounds or ulcers.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Participants with a history of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biological composition to belzutifan.\n* Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with belzutifan, breastfeeding participants are excluded from this study.\n* History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":631,"type":20},32,[24],"The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer.\n\nThe name of the study drug involved in this study is:\n\n\\- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)",[138,635,90,28,29,222,316,223],"Ovarian Carcinoma",[138,635,637,638,639,640,641,642,28,90,29,222,643,316,223],"Persistent Clear Cell Ovarian Carcinoma","Recurrent Clear Cell Ovarian Carcinoma","Clear Cell Uterine Carcinoma","Clear Cell Endometrial Carcinoma","Clear Cell Cervical Carcinoma","Clear Cell Vulvar Carcinoma","Gynecologic Malignancy",{"date":617,"type":40},{"date":646,"type":40},"2024-12-20",{"date":648,"type":20},"2029-06-30",{"name":650,"class":47},"Dana-Farber Cancer Institute",{"id":652,"slug":653,"hasResults":11,"nctId":654,"briefTitle":655,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":11,"sex":16,"minAge":657,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":660,"conditions":661,"keywords":686,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":48},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":659,"type":20},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,138,29,28,223,222,684,685],"ALS","Amyotrophic Lateral Sclerosis","Alzheimer Disease","Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Corticobasal Degeneration","Dementia","Frontotemporal Dementia","Huntington Disease","Lewy Body Disease","Multiple Sclerosis","Multiple System Atrophy","Parkinson Disease","Parkinson's Disease and Parkinsonism","Progressive Supranuclear Palsy","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","PTSD","Post Traumatic Stress Disorder",[662,663,664,667,668,669,670,671,672,673,674,675,687,677,678,679,688,689,683,690,138,29,28,223,222,684,685],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":693,"type":40},"2025-03-03",{"date":695,"type":40},"2022-11-10",{"date":697,"type":20},"2045-11-10",{"name":699,"class":47},"New York Stem Cell Foundation Research Institute",{"id":701,"slug":702,"hasResults":11,"nctId":703,"briefTitle":704,"officialTitle":704,"acronym":705,"eligibilityCriteria":706,"healthyVolunteers":336,"sex":57,"minAge":85,"maxAge":4,"enrollmentInfo":707,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":708,"conditions":709,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":718,"locationsCount":720},"100546289","evaluation-of-salivary-rna-in-subjects-scheduled-for-surgery-for-a-gynecologic-pathology-100546289","NCT06392997","Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology","GynRNA","Inclusion Criteria:\n\n1. Subject of legal age (according to local legislation) and at least 18 years old\n2. Subject (and if applicable her legal representative) having dated and signed the informed consent form\n3. Subject with a medical insurance policy\n4. Subject presenting to the department:\n\n   1. With Symptoms (bleeding and\u002For pain and\u002For clinically observed symptom) of one or more of the following pathologies (suspected undergoing diagnostic surgery\u002Fbiopsy or diagnosed and before any curative treatment of the pathology):\n\n      * Endometriosis\n      * Adenomyosis,\n      * Ovarian cysts,\n      * Fibroids,\n      * Ovarian cancer,\n      * Cervical cancer,\n      * Uterine cancer.\n   2. Asymptomatic with pap smear positive for cervical dysplasia or cervical cancer and before any curative treatment.\n   3. Asymptomatic undergoing a pap smear for cervical cancer screening in a gynecological follow-up context.\n\nExclusion Criteria:\n\n1. Recent (\\\u003C1 month) or ongoing bacterial or viral infection\n2. Known active oral or digestive mycosis\n3. Evolving oral pathology, symptomatic or obvious\n4. Known pregnancy\n5. Known current non-gynecological pelvic pathology\n6. Subject with a diagnosed breast cancer or cancer other than gynecological with the exception of basal cell carcinoma\n7. Subject with a history of treated cancer within the last 5 years with the exception of basal cell carcinoma\n8. Subject who has already received chemotherapy or radiotherapy or undergone complete or partial excision of the gynecological pathology of inclusion criterion\n9. Subject with significant difficulties reading or writing her language\n10. Subject unable to comply with study and\u002For follow-up procedures\n11. Participation in an interventional study with investigational drug or in the exclusion period of an interventional study.",{"count":570,"type":20},"GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics\u002Fgynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva.\n\nThe study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian\u002Fcervical\u002Futerine cancer) and asymptomatic females.\n\nThe patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations necessary according to the context, which are carried out according to the local recommendations.",[613,316,136,138,710,711,29,28],"Cyst Ovary","Fibroid","2025-01-20",{"date":714,"type":40},"2025-01-23",{"date":716,"type":40},"2024-12-05",{"date":97,"type":20},{"name":719,"class":75},"ZIWIG",13,{"id":722,"slug":723,"hasResults":11,"nctId":724,"briefTitle":725,"officialTitle":726,"acronym":4,"eligibilityCriteria":727,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":728,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":730,"conditions":731,"keywords":732,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":733,"lastUpdatePostDateStruct":734,"startDateStruct":736,"completionDateStruct":738,"leadSponsor":739,"locationsCount":48},"100515999","insights-into-participating-in-studies-for-uterine-cancer-100515999","NCT05998811","Insights Into Participating in Studies for Uterine Cancer","Exploring Uterine Cancer Clinical Trials - Revealing Participation Patterns in Individuals With Uterine Cancer","Inclusion Criteria:\n\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Diagnosis of uterine cancer\n* No prior treatment for uterine cancer\n\nExclusion Criteria:\n\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Enrolled in another research study\n* Inability to provide written informed consent",{"count":729,"type":20},500,"Clinical study participation has historically been heavily biased toward specific demographics.\n\nSeveral people will be invited to enroll in this trial so that it may collect a variety of data about uterine cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.\n\nPeople with uterine cancer who are invited to take part in medical study will benefit from the analysis of the data.",[28],[28],"2023-08-11",{"date":735,"type":40},"2023-08-21",{"date":737,"type":20},"2024-09",{"date":274,"type":20},{"name":740,"class":75},"Power Life Sciences Inc."]